---
title: "LifeMD partners with Halozyme unit Antares to launch XYOSTED telehealth self-pay program in July 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290431883.md"
description: "LifeMD has partnered with Antares Pharma, a Halozyme subsidiary, to launch an exclusive telehealth self-pay program for XYOSTED in July 2026. Initially covering 37 states, the program targets men with hypogonadism via virtual evaluations and lab tests. LifeMD handles clinical assessments and dispensing, offering an all-inclusive monthly price of approximately $249 without insurance requirements. The collaboration includes joint consumer education efforts."
datetime: "2026-06-22T12:01:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290431883.md)
  - [en](https://longbridge.com/en/news/290431883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290431883.md)
generator: "portal-rs"
---

# LifeMD partners with Halozyme unit Antares to launch XYOSTED telehealth self-pay program in July 2026

-   LifeMD entered an exclusive telehealth co-marketing collaboration with Antares Pharma, a Halozyme subsidiary, for a direct-to-patient self-pay program for XYOSTED. \* Program launch set for July 2026, initially covering 37 states, targeting men diagnosed with hypogonadism through virtual evaluation and lab testing. \* LifeMD’s affiliated medical group will handle clinical assessments; its pharmacy will be the preferred dispenser, shipping XYOSTED to patients’ homes. \* All-in monthly price set at about $249, covering medication, follow-up care, dose management, and refill support, with no insurance required. \* Parties plan joint consumer education and promotional spending; expansion tied to telehealth controlled-substance prescribing rules and potential insurance options. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750219) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)
- [LFMD.US](https://longbridge.com/en/quote/LFMD.US.md)
- [LFMDP.US](https://longbridge.com/en/quote/LFMDP.US.md)

## Related News & Research

- [Halozyme CEO Helen Torley sells USD 4.13 million in common shares](https://longbridge.com/en/news/296412342.md)
- [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md)
- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)
- [Monarch Alternative Capital sells eight seniors housing properties in portfolio exit](https://longbridge.com/en/news/296240718.md)
- [Young female investors’ pots ‘nearly £4,600 bigger than those belonging to men’](https://longbridge.com/en/news/296154079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**